scholarly journals Why cholesterol ester transfer protein (CETP) inhibitors have and will likely continue to fail in trials undertaken to increase blood concentrations of HDL-cholesterol and reduce cardiovascular events

2017 ◽  
Vol 2 (3) ◽  
Author(s):  
Sander J. Robins
Keyword(s):  
Cholesterol Ester ◽  
Cardiovascular Events ◽  
Hdl Cholesterol ◽  
Cholesterol Ester Transfer Protein ◽  
Blood Concentrations ◽  
Transfer Protein ◽  
Cetp Inhibitors

scholarly journals Cholesterol Ester Transfer Protein Inhibitor Review

2017 ◽  
Vol 52 (9) ◽  
pp. 596-598
Author(s):  
Jerry Hu ◽  
Scot Walker
Keyword(s):  
Cholesterol Ester ◽  
Cardiovascular Events ◽  
Large Scale ◽  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Cholesterol Ester Transfer Protein ◽  
Lipoprotein Cholesterol ◽  
Blood Cholesterol ◽  
Transfer Protein ◽  
Primary Means

Treatment of blood cholesterol is part of a strategy to lower atherosclerotic cardiovascular (ASCVD) risk. While use of HMG-CoA reductase inhibitors to modify cholesterol levels is the primary means of lowering the risk of an ASCVD event, residual risk remains. A new strategy being investigated is the use of cholesterol ester transfer protein (CETP) inhibitors to raise the levels of high-density lipoprotein cholesterol (HDL-C) and lower low-density lipoprotein cholesterol (LDL-C). While initial large-scale studies demonstrated no reduction of cardiovascular events, one CETP inhibitor, anacetrapib, has demonstrated a reduction in cardiovascular events in the REVEAL trial.

Sign in / Sign up

Export Citation Format

Share Document